BioPharmSignal logoBioPharmSignal

Biotech News

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesCompany update

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on May 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted

Open original release

Related news

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

PRAXPraxis Precision Medicines2026-04-14 11:30 EST

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-05-01 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-04-03 20:15 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-06-05 12:01 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-03-16 20:05 EST

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Praxis Precision Medicines

Praxis Precision Medicines is a neuroscience company focused on precision approaches to brain disease and movement disorders. Its platform aims to translate genetics and neurobiology into treatment options.

Recent company news

PRAXPraxis Precision Medicines2026-06-01 20:15 EST

Praxis Precision Medicines Provides Vormatrigine Program Update

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-05-05 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

PRAXPraxis Precision Medicines2026-04-14 11:30 EST

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Stock data

Close
315.80 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States